Woodline Partners’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $24.4M | Buy |
+772,976
| New | +$24.4M | 0.13% | 236 |
|
|
2025
Q1 | – | Sell |
-423,828
| Closed | -$15.3M | – | 1024 |
|
|
2024
Q4 | $15.3M | Buy |
423,828
+235,257
| +125% | +$8.51M | 0.1% | 260 |
|
|
2024
Q3 | $5.88M | Buy |
+188,571
| New | +$5.88M | 0.05% | 369 |
|
|
2024
Q2 | – | Sell |
-1,291,291
| Closed | -$44M | – | 659 |
|
|
2024
Q1 | $44M | Buy |
+1,291,291
| New | +$44M | 0.41% | 68 |
|
|
2023
Q1 | – | Sell |
-105,878
| Closed | -$3.78M | – | 768 |
|
|
2022
Q4 | $3.78M | Sell |
105,878
-687,889
| -87% | -$24.5M | 0.05% | 360 |
|
|
2022
Q3 | $26.9M | Buy |
793,767
+225,188
| +40% | +$7.62M | 0.38% | 75 |
|
|
2022
Q2 | $16.4M | Buy |
568,579
+83,167
| +17% | +$2.41M | 0.25% | 122 |
|
|
2022
Q1 | $15.7M | Buy |
+485,412
| New | +$15.7M | 0.25% | 121 |
|
|
2021
Q4 | – | Sell |
-53,915
| Closed | -$1.44M | – | 783 |
|
|
2021
Q3 | $1.44M | Buy |
+53,915
| New | +$1.44M | 0.02% | 468 |
|